Novel Drug Delivery Systems in the Management of CNS Disorders offers a comprehensive source of information on delivering drugs to the central nervous system to treat various diseases and conditions. The book covers a wide range of CNS disorders, including epilepsy, Parkinson's, Alzheimer's, Huntington's, multiple sclerosis, schizophrenia, cerebral palsy, autism, ALS, and others. The book begins by presenting the foundations of drug delivery to the brain and addressing the associated challenges. It then delves into clinical trials and explores the future potential of the presented technologies. This reference is designed for drug delivery researchers in academia and corporations, providing them with the essential knowledge about overcoming the Brain-Blood Barrier and achieving targeted drug delivery to the central nervous system.
1. Novel Drug Delivery Systems in the management of CNS Disorders - p. i 2. Cover - p. i 3. Title Page - p. ii 4. Copyright Page - p. iii 5. Table of Contents - p. iii 6. Dedication - p. iv 7. Contributors - p. xvii 8. About editors - p. xxi 9. Foreword - p. xxiii 10. Preface - p. xxv 11. Chapter 1 General anatomy and physiology of the brain - p. 3 12. Chapter 2 Drug delivery to brain: Formulation challenges and potential approaches - p. 15 13. Chapter 3 Possible targets in the management of various CNS disorders - p. 39 14. Chapter 4 Antioxidants and their possible benefits in neurodegeneration - p. 49 15. Chapter 5 Prodrug approaches for delivering CNS active agents - p. 63 16. Chapter 6 Traditional practices in CNS drug delivery - p. 79 17. Chapter 7 Emerging need of novel drug delivery systems in management of CNS disorders - p. 93 18. Chapter 8 Nose to brain drug delivery through advanced drug delivery systems - p. 105 19. Chapter 9 Physiologically based pharmacokinetic (PBPK) modeling for CNS delivery - p. 121 20. Chapter 10 Superparamagnetic iron oxide nanoparticles and their potential role in the diagnosis and therapeutics of various neurological disorders - p. 133 21. Chapter 11 Novel drug delivery systems in treating epilepsy: An update - p. 167 22. Chapter 12 Novel drug delivery system in the management of Parkinson’s disease - p. 185 23. Chapter 13 Role of novel drug delivery systems in managing Alzheimer's disease - p. 199 24. Chapter 14 Novel drug delivery systems in the management of Huntington's disease - p. 215 25. Chapter 15 Advancing insights into vistas of novel drug delivery approaches for multiple sclerosis treatment-a review - p. 225 26. Chapter 16 Role of novel drug delivery systems in delivering antidepressant drugs to the brain - p. 235 27. Chapter 17 Delivering cancer chemotherapeutics to the brain through novel drug delivery system - p. 247 28. Chapter 18 Promising novel drug delivery approaches in the development of therapeutics for schizophrenia disease management - p. 261 29. Chapter 19 Prospects of novel drug delivery systems in treating cerebral palsy - p. 269 30. Chapter 20 Novel treatment in managing autism - p. 277 31. Chapter 21 Novel drug delivery systems in amyotrophic lateral sclerosis - p. 285 32. Chapter 22 Novel drug delivery systems in cerebral vascular disorders, transient ischaemic attack, and stroke interventions - p. 295 33. Chapter 23 Treating meningitis through novel drug delivery system - p. 313 34. Chapter 24 Treatment of CNS infections in AIDS positive patients through novel drug delivery systems - p. 321 35. Chapter 25 Novel drug delivery system in the management of myasthenia gravis - p. 333 36. Chapter 26 Etiology and treatment challenges for neurotraumatic and psychiatric disorders - p. 343 37. Chapter 27 Decrypting the trends in delivery of drugs to brain for treatment of neuropathy - p. 353 38. Chapter 28 Delivery of antimigraine drugs to the brain through novel drug delivery systems - p. 371 39. Chapter 29 Treatment of heavy metal induced neurotoxicity via advanced drug delivery systems - p. 393 40. Chapter 30 Exploring the potential of artificial intelligence in drug delivery to brain - p. 411 41. Chapter 31 Advanced drug delivery systems in the management of CNS disorders - p. 429 42. Chapter 32 Future prospects and challenges to central nervous system drug delivery; A shortcoming towards treatment of neurodegenerative disease - p. 451 43. Appendix - p. 463 44. Index - p. 469 45. Index - Continued - p. 477
Novel Drug Delivery Systems in the Management of CNS Disorders offers a comprehensive source of information on delivering drugs to the central nervous system to treat various diseases and conditions. The book covers a wide range of CNS disorders, including epilepsy, Parkinson's, Alzheimer's, Huntington's, multiple sclerosis, schizophrenia, cerebral palsy, autism, ALS, and others. The book begins by presenting the foundations of drug delivery to the brain and addressing the associated challenges. It then delves into clinical trials and explores the future potential of the presented technologies. This reference is designed for drug delivery researchers in academia and corporations, providing them with the essential knowledge about overcoming the Brain-Blood Barrier and achieving targeted drug delivery to the central nervous system.
1. Novel Drug Delivery Systems in the management of CNS Disorders - p. i 2. Cover - p. i 3. Title Page - p. ii 4. Copyright Page - p. iii 5. Table of Contents - p. iii 6. Dedication - p. iv 7. Contributors - p. xvii 8. About editors - p. xxi 9. Foreword - p. xxiii 10. Preface - p. xxv 11. Chapter 1 General anatomy and physiology of the brain - p. 3 12. Chapter 2 Drug delivery to brain: Formulation challenges and potential approaches - p. 15 13. Chapter 3 Possible targets in the management of various CNS disorders - p. 39 14. Chapter 4 Antioxidants and their possible benefits in neurodegeneration - p. 49 15. Chapter 5 Prodrug approaches for delivering CNS active agents - p. 63 16. Chapter 6 Traditional practices in CNS drug delivery - p. 79 17. Chapter 7 Emerging need of novel drug delivery systems in management of CNS disorders - p. 93 18. Chapter 8 Nose to brain drug delivery through advanced drug delivery systems - p. 105 19. Chapter 9 Physiologically based pharmacokinetic (PBPK) modeling for CNS delivery - p. 121 20. Chapter 10 Superparamagnetic iron oxide nanoparticles and their potential role in the diagnosis and therapeutics of various neurological disorders - p. 133 21. Chapter 11 Novel drug delivery systems in treating epilepsy: An update - p. 167 22. Chapter 12 Novel drug delivery system in the management of Parkinson’s disease - p. 185 23. Chapter 13 Role of novel drug delivery systems in managing Alzheimer's disease - p. 199 24. Chapter 14 Novel drug delivery systems in the management of Huntington's disease - p. 215 25. Chapter 15 Advancing insights into vistas of novel drug delivery approaches for multiple sclerosis treatment-a review - p. 225 26. Chapter 16 Role of novel drug delivery systems in delivering antidepressant drugs to the brain - p. 235 27. Chapter 17 Delivering cancer chemotherapeutics to the brain through novel drug delivery system - p. 247 28. Chapter 18 Promising novel drug delivery approaches in the development of therapeutics for schizophrenia disease management - p. 261 29. Chapter 19 Prospects of novel drug delivery systems in treating cerebral palsy - p. 269 30. Chapter 20 Novel treatment in managing autism - p. 277 31. Chapter 21 Novel drug delivery systems in amyotrophic lateral sclerosis - p. 285 32. Chapter 22 Novel drug delivery systems in cerebral vascular disorders, transient ischaemic attack, and stroke interventions - p. 295 33. Chapter 23 Treating meningitis through novel drug delivery system - p. 313 34. Chapter 24 Treatment of CNS infections in AIDS positive patients through novel drug delivery systems - p. 321 35. Chapter 25 Novel drug delivery system in the management of myasthenia gravis - p. 333 36. Chapter 26 Etiology and treatment challenges for neurotraumatic and psychiatric disorders - p. 343 37. Chapter 27 Decrypting the trends in delivery of drugs to brain for treatment of neuropathy - p. 353 38. Chapter 28 Delivery of antimigraine drugs to the brain through novel drug delivery systems - p. 371 39. Chapter 29 Treatment of heavy metal induced neurotoxicity via advanced drug delivery systems - p. 393 40. Chapter 30 Exploring the potential of artificial intelligence in drug delivery to brain - p. 411 41. Chapter 31 Advanced drug delivery systems in the management of CNS disorders - p. 429 42. Chapter 32 Future prospects and challenges to central nervous system drug delivery; A shortcoming towards treatment of neurodegenerative disease - p. 451 43. Appendix - p. 463 44. Index - p. 469 45. Index - Continued - p. 477
